Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9668057 | 0.84 | MMP2 (0.40) | CA2MAPK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3020928 | 0.84 | CHRM1 (0.56) | CA2MAPK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3014658 | 0.80 | CA2 (0.68) | CA2MAPK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL30320036 | 0.80 | GABRR1 (0.43) | CA2MAPK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3018124 | 0.80 | CA2 (0.36) | CA2MAPK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1300143 | 0.80 | FOLH1 (0.46) | HDAC1HDAC2FFAR3 | |
| SCHEMBL17060892 | 0.78 | CA2 (0.34) | CA2MAPK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1539084 | 0.78 | CA2 (0.34) | CA2MAPK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3616152 | 0.77 | CA2 (0.47) | CA2MAPK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL15656133 | 0.75 | TSHR (0.42) | CA2MAPK1SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020002138-A1 | C5 OR C6 ACID ESTER-BASED CATALYST AND USE THEREOF IN A HYDROPROCESSING AND/OR HYDROCRACKING PROCESS | IFP Energies Nouvelles (FR) | 2020-01-02 | — | — | WO | claimed |
| US-20080233619-A1 | Process For the Enantioselective Enzymatic Reduction of Keto Compounds | IEP GMBH (DE) | 2008-09-25 | — | — | US | claimed |
| EP-1635806-B1 | METHOD FOR TREATING ALCOHOLIC HEPATITIS | UNIV PITTSBURGH (US) | 2008-05-28 | — | — | EP | claimed |
| EP-1233767-B1 | PYRUVATE ESTER COMPOSITION AND METHOD OF USE FOR RESUSCITATION AFTER EVENTS OF ISCHEMIA AND REPERFUSION | XANTHUS LIFE SCIENCES INC (CA) | 2006-04-12 | — | — | EP | claimed |
| EP-1494659-B1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-KETOALKANOIC ACID ESTER OR -AMIDE AND LACTIC ACID OR A LACTIC ACID SALT | CRITICAL THERAPEUTICS INC (US) | 2005-10-12 | — | — | EP | claimed |
| US-12417818-B1 | Total mutational burden (TMB) estimate | Ocean Genomics, Inc. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20240199611-A1 | ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2024-06-20 | — | — | US | disclosed |
| EP-4028399-B1 | ANTIBACTERIAL COMPOUNDS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2024-02-14 | — | — | EP | disclosed |
| EP-4308239-A1 | ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022228652-A1 | MEANS AND METHOD FOR TREATING VIRAL INFECTIONS | BIRKENMEIER GERD (DE) | 2022-11-03 | — | — | WO | disclosed |
| US-20220340564-A1 | ANTIBACTERIAL COMPOUNDS | JANSSEN-CILAG (FR) | 2022-10-27 | — | — | US | disclosed |
| WO-2022194803-A1 | ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-09-22 | — | — | WO | disclosed |
| WO-2005037788-A1 | NOVEL METHOD FOR PREPARATION OF CRYSTALLINE PERINDOPRIL ERBUMINE | LUPIN LTD. (IN) | 2005-04-28 | — | — | WO | disclosed |
| EP-1509225-A1 | METHOD FOR THE USE OF PYRANOINDOLE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | Wyeth (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2004075889-A1 | PROCESS FOR PREPARATION OF PERINDOPRIL AND SALTS THEREOF | LUPIN LIMITED (IN) | 2004-09-10 | — | — | WO | disclosed |
| EP-1437401-A1 | Oxidoreductase | Juelich Enzyme Products GmbH (DE) | 2004-07-14 | — | — | EP | disclosed |
| US-20040082643-A1 | Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus | WYETH (US) | 2004-04-29 | — | — | US | disclosed |
| WO-2003099275-A1 | METHOD FOR THE USE OF PYRANOINDOLE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2003-12-04 | — | — | WO | disclosed |
| EP-0739199-A1 | ESTRADIOL PENETRATION INTENSIFIER FOR TRANSDERMAL ADMINISTRATION | LTS LOHMANN Therapie-Systeme GmbH (DE) | 1996-10-30 | — | — | EP | disclosed |
| WO-1995019162-A1 | ESTRADIOL PENETRATION INTENSIFIER FOR TRANSDERMAL ADMINISTRATION | LTS LOHMANN THERAPIE-SYSTEME GMBH & CO. KG (DE) | 1995-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199611-A1 | ANTIBACTERIAL COMPOUNDS | FDPS, MT-ND4, NDUFS3 | CA2 3021/4885MAPK1 3767/4885SLC1A3 4692/4885 |
| US-20040082643-A1 | Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus | HAVCR2, HCCS, ZC3HAV1 | CA2 4572/4885MAPK1 2864/4885SLC1A3 2691/4885 |
| US-20220340564-A1 | ANTIBACTERIAL COMPOUNDS | FDPS, SQOR, NDUFS3 | CA2 3368/4885MAPK1 3763/4885SLC1A3 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.